Pharmaceuticals News and Research

RSS

Bayer's gadobutrol injection for CNS imaging receives FDA Advisory Committee approval

Bayer HealthCare Pharmaceuticals Inc. announced today that the Peripheral and Central Nervous System Drugs Advisory Committee to the U.S. Food and Drug Administration voted unanimously that clinical trial and postmarketing data for gadobutrol injection, a macrocyclic 1.0 molar gadolinium-based contrast agent (GBCA), support approval of the product for proposed use in diagnostic magnetic resonance imaging (MRI) in adults and children.

24 Jan 2011

SuppreMol completes successful pre-IND meeting with U.S. FDA

SuppreMol GmbH, a privately held biopharmaceutical company developing innovative therapeutics for the treatment of autoimmune diseases, today announced that it has successfully completed a pre-Investigational New Drug Application (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for its lead compound SM101, which is being developed for the treatment of Primary Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE).

24 Jan 2011

Eckert & Ziegler receives European Commission's indefinite approval for YTTRIGA

Eckert & Ziegler Strahlen- und Medizintechnik AG, a firm specializing in radioactive compounds for the treatment of cancer, has renewed the approval of its drug YTTRIGA (Yttrium-90 chloride) by the European Commission. Five years ago the European Medicines Agency EMA approved this drug for the first time and as a result of the current renewal process the drug has now been granted an indefinite approval.

24 Jan 2011

China Shenghuo's Lixuwang product recieves Chinese Well-Known Trademark Honor

China Shenghuo Pharmaceutical Holdings, a China-based pharmaceutical company engaged in the research, development, manufacture, and marketing of Traditional Chinese Medicine, nutritional supplement and cosmetic products, today announced that "Lixuwang", the trademark of its best selling product, Xuesaitong Capsule, was awarded the Chinese Well-Known Trademark Honor by the State Administration for Industry and Commerce of China.

24 Jan 2011

Teva Pharmaceutical announces entry into new three-year credit facility

Teva Pharmaceutical Industries Ltd. announced today that it has entered into a new three-year, $1.5 billion unsecured revolving credit facility, which replaces and expands existing credit lines at terms that are more favorable to Teva.

24 Jan 2011

Immunomedics reports encouraging results from Y-90-labeled clivatuzumab tetraxetan study in pancreatic cancer

Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that repeated therapy cycles of its proprietary antibody, clivatuzumab tetraxetan, labeled with yttrium-90 plus low-dose gemcitabine, extended median overall survival.

21 Jan 2011

Novel FAK inhibitors targeting binding site of VEGFR-3 reduce growth of pancreatic cancer cells

CureFAKtor Pharmaceuticals, LLC, a privately-held biopharmaceutical company focused on the research and development of Focal Adhesion Kinase (FAK) inhibitors for cancer, today presented research results at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco demonstrating that novel FAK inhibitors targeting the binding site of vascular endothelial growth factor receptor 3 (VEGFR-3) reduced the growth of pancreatic cancer cells in vitro and in vivo.

21 Jan 2011

Watson predicts $4.2 billion in revenues from Global Generics and Global Brand businesses

During an investor meeting held today in New York, NY, Watson Pharmaceuticals, Inc. provided an update on its Global businesses, including a detailed overview of its commercial operations and pipeline developments within its Global Generics and Global Brands businesses, and an update of achievements within its Global Operations. In conjunction with the meeting, the Company provided its preliminary 2011 financial and long term growth forecasts.

21 Jan 2011

Jiangbo Pharmaceuticals reaches settlement with debenture holders

Jiangbo Pharmaceuticals, Inc., a pharmaceutical company with its principal operations in the People's Republic of China, today announced that it has reached a settlement with the holder of its November 2007 Debenture and with the holders of its May 2008 Notes under which the Company has agreed to issue to such holders a total of 886,277 shares of its common stock as a payment for all delinquent interest and associated penalties with respect to its November 2007 Debenture and May 2008 Notes.

21 Jan 2011

Sunshine and Binghamton University enter research agreement for cancer compound

Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has executed an agreement with The Research Foundation of the State University of New York (SUNY), acting for and on behalf of Binghamton University (Binghamton, NY).

21 Jan 2011

GSK, Valeant receive European CHMP positive opinion for Trobalt

GlaxoSmithKline and Valeant Pharmaceuticals International, Inc. announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending marketing authorisation for Trobalt™ (retigabine) as an adjunctive treatment of partial onset seizures, with or without secondary generalisation in adults aged 18 years and above with epilepsy.

21 Jan 2011

Approaches designed to motivate drug development for children needed

Recent legislative and regulatory actions make great strides toward establishing much needed incentives for pharmaceutical companies and others to develop and test more medications for pediatric rare diseases, including pediatric cancers, according to commentary by experts from Children's National Medical Center. The commentary appears in the January 19 issue of Science Translational Medicine.

21 Jan 2011

inVentiv Health to acquire Campbell Alliance and i3

inVentiv Health, Inc., a leading provider of outsourced clinical development, launch and commercialization services to the global healthcare industry, today announced that it has signed a definitive agreement to acquire Campbell Alliance, a leading management consulting firm specializing in serving the pharmaceutical and biotech industries. Yesterday, inVentiv announced that it has signed a definitive agreement to purchase i3 from Ingenix.

From Thermo Fisher Scientific Inc. 21 Jan 2011

Vibrio cholerae kills E. coli bacteria

Just over a year after the earthquake in Haiti killed 222,000 people there's a new problem that is killing Haitians. A cholera outbreak has doctors in the area scrambling and the water-borne illness has already claimed 3600 lives according to officials with M-dicin Sans Fronti-res (Doctors without Borders).

21 Jan 2011

Northeast Ohio healthcare sector companies attracted $132 million in investments in 2010

In 2010, 62 Northeast Ohio companies collectively raised $221 million from venture capitalists and angel investors, an increase of 121 percent over the amount raised by companies in 2009. The growth rate of dollars invested in regional companies is higher than recently released data from Thomson Reuters showing a 19 percent increase in dollars invested nationally.

21 Jan 2011

Teva invests $3.95M in Rexahn for development of anti-cancer compound RX-3117

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, announced that Teva Pharmaceutical Industries Limited (Teva) purchased 2,334,515 shares of Rexahn's common stock in a private offering for $3.95 million, or $1.692 per share.

21 Jan 2011

Opinions: GAVI; Haitian women; Clinton's foreign policy

"Vaccines are among the greatest scientific contributions to human welfare. They are also some of the largest humanitarian contributions of developed nations to the rest of the world. So it is unfortunate that a decade of vaccine controversy has overshadowed a decade of vaccine miracles," Washington Post columnist Michael Gerson writes in an opinion piece reflecting on the contributions of the GAVI Alliance over the past decade.

21 Jan 2011

EHSI's NASA bioreactor will help reduce pain and trauma caused by harvesting of adult stem cells

Emerging Healthcare Solutions, Inc. expects that the company's NASA-developed bioreactor will help reduce patients' pain and trauma caused by the harvesting of adult stem cells for therapeutic and research purposes, said EHSI President and CEO Cindy Morrissey.

21 Jan 2011

Major breakthrough: Genome-based medicine for treatment of alcoholism

For the first time in alcohol addiction research, UVA investigators have successfully treated alcohol-dependent individuals with medication that is tailored specifically to match their genetic profile.

21 Jan 2011

Supreme Court considers drug-pricing lawsuit

The U.S. Supreme Court questioned in oral arguments whether local governments and their hospitals can sue pharmaceutical companies over drug-pricing agreements with HHS.

21 Jan 2011